Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cipher Mining Inc (CIFR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Cipher Mining IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Cipher Mining Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Cipher Mining Inc trades at $19.75 (market cap $8.13B), while Regeneron Pharmaceuticals Inc trades at $655.64 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.5× Cipher Mining Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.

CIFRREGN
Market Cap
$8.13B$68.79B
Sector
Basic MaterialsHealth
52-Week High
$29.18$812.27
52-Week Low
$4.72$542.52
Enterprise Value
$12.16B$62.74B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cipher Mining Inc

CIFR trades at $20.085, down 9.16% over 24 hours, reflecting bearish technical signals despite unanimous analyst buy ratings. The company is transitioning from Bitcoin mining to AI data center operations, evidenced by a $11.4B contracted revenue backlog but faces significant financial strain with a -427.79% net income margin and negative cash flow from operations. Recent news highlights volatility driven by AI infrastructure developments and capital raises.

The outlook hinges on successful execution of its AI data center pivot, offering substantial upside to the $32.81 consensus price target, but high valuation multiples and persistent losses pose near-term risks. Investors must weigh transformative growth potential against cash burn and execution challenges in a competitive sector.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.

The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cipher Mining Inc

Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.

Read more on CIFR

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN